Stevenage Bioscience Catalyst is an independent facility that was formed as a joint venture between UK Department of Business, Innovation and Skills (BIS), GlaxoSmithKline (GSK), the Wellcome Trust, the East of England Development Agency, and the Technology Strategy Board. The site opened for business in February 2012, and this is the first academic tenant to join the community.
To read the full, original article click on this link: Gene clue to drug resistance in African sleeping sickness | Wellcome Trust
